Phase-II trials in patients with urothelial tract tumors. Memorial Sloan-Kettering Cancer Center.
Phase-II trials in patients with urothelial tract tumors. Memorial Sloan-Kettering Cancer Center.
复制标题
尿路上皮肿瘤患者的 II 期试验。
DOI：
10.1007/bf00256709
复制
发表时间：
1983
影响因子：
3
通讯作者：
Yagoda,A
中科院分区：
文献类型：
--
作者：
Yagoda,A
在晚期尿路上皮肿瘤患者的治疗方面取得了重大进展，在选定的患者中使用系统的II期方法。在这个时候，DDP和MTX，单独，似乎诱导最大数量的响应，而VLB和ADM，单独，是很好的第二代理。DDP+ADM和VLB+MTX的组合似乎比单一药物组分更有效，并且希望四种药物组合可能更有效。由于目前可用的药物具有显著的抗肿瘤活性，我们计划在术前放疗和根治性膀胱癌伴淋巴结清扫后的D期肿瘤患者中开展一项随机III期研究。纪念斯隆-凯特琳癌症中心的数据表明，尽管进行了放射治疗和化疗，1年的死亡率为70%，2年的死亡率为87%;因此，对于这些病例，化疗可能有助于延长生存期。虽然新的药物仍然需要被定义，尿路移行细胞癌必须被认为是一种对化疗有反应的肿瘤;我们可能已经进入了化疗治愈性治疗的门槛。
Major progress has been made in the treatment of patients with advanced urothelial tract tumors, using a systematic phase II approach in selected patients. At this time, DDP and MTX, singly, seem to induce the largest number of responses, while VLB and ADM, singly, are good secondary agents. The combinations of DDP+ADM, and VLB+MTX appear to be somewhat more effective than the single drug components, and hopefully a four-drug combination may be even more effective. Since significant antitumor activity is achieved with the drugs now available, we plant to initiate a randomized phase-III study in patients with stage-D tumors after preoperative irradiation and radical cystectomy with lymph node dissection. The data at Memorial Sloan-Kettering Cancer Center indicate a 70% death rate at 1 year, and 87% at 2 years, despite radiation therapy and cystectomy; for such cases, therefore, chemotherapy may be useful in prolonging survival. While new drugs still need to be defined, transitional cell carcinoma of the urothelial tract must be considered a tumor responsive to chemotherapy; we may possibly be on the threshold of chemotherapeutically curative therapies.